At ESMO, good news from AstraZeneca's immuno-oncology division

9 September 2017
astrazeneca_flickr_big

Another key presentation at the European Society of Medical Oncology congress offers AstraZeneca (LSE: AZN) hope of escaping the pall cast over the company by the high profile failure of its MYSTIC trial earlier in the year.

Results from a planned interim analysis of the Phase III PACIFIC trial show an improvement in progression-free survival (PFS) in certain patients with inoperable non-small cell lung cancer (NSCLC).

The trial compares the Anglo-Swedish firm's candidate checkpoint inhibitor Imfinzi (durvalumab) with the current chemotherapeutic standard of care.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical